The interrelation of CYP2C9, CYP4F2, VKORC1 genes polymorphism and hemorrhagic complications of warfarin therapy in patients with atrial fibrillation: a single-center one-year study
Article Sidebar
Main Article Content
Abstract
The aim – to evaluate the effectiveness and safety of warfarin therapy in patients with atrial fibrillation (AF) in the anticoagulation practice, the rate of CYP2C9, CYP4F2, VKORC1 genes polymorphism and their interrelation with hemorrhagic complications among Zaporizhzhia region residents.
Material and methods. We studied 41 patients with AF (mean age – 68.2±1.2 years, men – 19, women – 22) enrolled in a 1-year out-patient observation in the anticoagulation practice of Zaporizhzhia State Medical University clinics. All patients were treated with warfarin. CYP2C9, CYP4F2, VKORC1 genes polymorphism was determined using polymerase chain reaction method.
Results. During one year hemorrhagic complications (small bleedings) arose in 22 (53.66 %) patients with AF, receiving warfarin therapy. Bleedings were significantly more frequent in the group of patients with VKORC1 gene mutation: 69.5 % vs. 37.5 %, respectively (χ2=5.331; Р<0.05). It was found that the relative risk of bleeding under warfarin treatment in patients with VKORC1 gene mutation is 1.97 (95 % CI 1.039; 3.751; Р<0.05).
Conclusions. VKORC1 polymorphism is associated with increased frequency of hemorrhagic complications in patients with AF taking warfarin, indicating the relevance of a personalized approach to the warfarin dose titration using pharmacogenetic testing.
Article Details
Keywords:
References
Gavrisyuk EV, Syichev DA., Kazakov RE, Kossovskaya AV, Marinin VF. Experience of using pharmacogenetic testing to personalize the dosage of warfarin in polyclinic conditions Tihookeanskiy meditsinskiy zhurnal [Pacific Medical Journal] 2015;1:60–62 (in Russ).
Dziak HV, Zhariniv OI. Atrial fibrillation Chetverta khvylia,2011.192 р (in Ukr.).
Syichev DA. Predictors of cardiovascular events in patients with fibrillation and atrial flutter of non-valvular origin. Kachestvennaya Klinicheskaya Praktika [Qualitative clinical practice] 2011;1:4–10 (in Ukr).
Sychov OS, Borodai ES, Borodai AO. Recommendations for the use of pharmacogenetic testing in clinical practice. Ukrainskii kardiologichnii zhurnal [Ukrainian Journal of Cardiology] 2016;6:64–75 (in Russ).
Tseluyko VI, Opolonskaya NA. Prevalence of risk factors for thromboembolic and hemorrhagic complications among patients with atrial fibrillation. Meditsina neotlozhnyih sostoyaniy [Emergency medicine] 2013;7:65–69 (in Russ).
Buzoianu A, Trifa A, Mureєanu D, Criєan S. Analysis of CYP2C9*2 , CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. Journal of Cellular and Molecular Medicine 2012;16(12):2919–2924.
Daly A. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Archives of Toxicology 2013;87(3):407–420.
Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Annal of Internal Medicine 1993;118(7):511–520.
Johnson JА, Gong L, Whirl-Carrillo M, Gage B, Scott S, Stein C, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology & Therapeutics 2011; 90(4):625–629.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu B, Schotten U, Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18(11):1609–1678.
Mazur-Bialy AI, Zdebska K, Wypasek E, Undas A. Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants. Thrombosis research 2013;131(3):279–280.
Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa, K., Matsumoto M, Kojima T, Hanada S, Nomoto K, Arima K, Takahashi F, Kotani T, Ikeya Y, Fukushima S, Itoh S, Kondo K, Chiku M, Ohno Y, Onikura M, Hirayama A. Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry. Journal of Arrhythmia 2017;33(4):289–296.
Potpara T, Larsen T, Deharo J, Rossvoll O, Dagres N, Todd D, Pison L, Proclemer A, Purefellner H, Blomstrцm-Lundqvist C. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). Europace 2015;17(6):986–993.
Rusdiana T, Araki T, Nakamura T, Subarnas A, Yamamoto K. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. European Journal Of Clinical Pharmacology 2012;69(3):395–405.
Teh L, Langmia I, Fazleen Haslinda M, Ngow H, Roziah M, Harun R, Zakaria Z, Salleh M. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. Journal of Clinical Pharmacy and Therapeutics 2011;37(2):232–236.
Zhu Y, Shennan M, Reynolds K, Johnson N, Herrnberger M, Valdes R, Linder M. Estimation of Warfarin Maintenance Dose Based on VKORC1 (-1639 G>A) and CYP2C9 Genotypes. Clinical Chemistry 2007;53(7):1199–1205.